How does IFPMA view coercive IP waivers versus voluntary sharing?

Question

Accepted Answer

IFPMA Views Coercive IP Waivers as Harmful to Innovation, Preferring Voluntary Knowledge Sharing

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) views coercive intellectual property (IP) waivers as a detrimental approach that would undermine innovation, contrasting it sharply with the benefits of voluntary knowledge sharing. Thomas Cueni, director general of IFPMA, articulated that such compulsory measures pose significant risks to the pharmaceutical industry's ability to invest in and develop new treatments. He emphasized that the process of developing new medical countermeasures requires substantial investment and that the security of IP rights is fundamental to encouraging this risk-taking.
Risk to Investment and Innovation

Cueni stated that manufacturers would be unwilling to invest significant resources into potential new products if their intellectual property rights could be easily revoked. This perspective highlights a core concern within the pharmaceutical sector: that the prospect of IP protection is a primary driver for the high-risk, high-reward research and development necessary for groundbreaking medical advancements. The IFPMA argues that the potential for IP to be stripped away deters the substantial financial commitments required to bring novel treatments from concept to market, thereby stifling future innovation.
Danger of Coercive Measures

The IFPMA considers the shift from voluntary knowledge sharing to a "coercive" situation to be "seriously dangerous." This sentiment underscores a belief that mandated IP relinquishment undermines the collaborative spirit that can emerge during crises. Cueni noted that even in situations where knowledge and technology are shared, generic manufacturers often depend on the ongoing support and expertise of the original patent holders. A coercive environment, conversely, would likely disrupt these established, mutually beneficial relationships.
Reliance on Patent Holders for Generic Production

Cueni further elaborated that generic manufacturers remain reliant on close support from patent holders when knowledge and technology are transferred. This indicates that the process of scaling up production for treatments, even by generic companies, is not a simple matter of handing over a formula. It involves intricate technical assistance, quality control guidance, and ongoing collaboration, all of which are facilitated when IP rights are respected and voluntary partnerships are in place. The IFPMA suggests that coercive measures would jeopardize this essential, practical support system.

Reading history

Hide →

This history is cleared when the page is closed.

How does IFPMA view coercive IP waivers versus voluntary sharing?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends